Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients

Summary

The purpose of this study was to assess the safety and describe the steady-state plasma pharmacokinetic (PK) profiles of Travoprost ophthalmic solution, 0.004% (new formulation) following a once daily administration for 7 days in pediatric glaucoma or ocular hypertension patients.

Timeline

Start

2013-01

Primary completion

2013-07

Completion

2013-07

Drugs

Indications